New alpha therapy shows promise for deadly brain cancer
NCT ID NCT07488754
First seen Apr 07, 2026 · Last updated May 12, 2026 · Updated 8 times
Summary
This study tests a new treatment for aggressive brain tumors (glioblastoma) that uses a radioactive substance attached to a targeting molecule to deliver radiation directly to cancer cells. It is for adults aged 18-80 who have completed standard therapy but need extra treatment. The goal is to see if this approach can extend survival and slow tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Neurosurgery, Medical University of Warsaw, Banacha 1a
RECRUITINGWarsaw, Poland, 02-097, Poland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Department of Neurosurgery, National Instiute of Oncology, W.K. Roentgena 5
RECRUITINGWarsaw, Poland, 02-781, Poland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.